Skip to main content
. 2016 Jun 3;6:27175. doi: 10.1038/srep27175

Figure 2. Duration of rCV02-induced immunity in 3 × Tg-AD mice following prophylactic or therapeutic administration.

Figure 2

Serum samples from 3 × Tg-AD mice immunized with rCV02 were collected at the time-points indicated (Supplementary Figure S1) and the anti-Aβ42 IgG titers were analyzed by ELISA. Serum samples from individual mice were assayed, and the geometric mean titer (GMT) was calculated for each group (n = 8). The serum antibody titer was monitored for 14 months for the prophylactic treatment (A) and 7 months for the therapeutic treatment (B). The x-axis indicates the age of the mice at the time of the blood sampling (months). The solid arrows indicate the time of rCV02 vaccine administration.